Business
Telo Genomics Announces Publication of Results from Its Smoldering Myeloma Clinical Study in the American Journal of Hematology
Toronto, Ontario--(Newsfile Corp. - May 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDS...
About this update from Telo Genomics Corp.
[{"type":"text","content":"Telo Genomics Announces Publication of Results from Its Smoldering Myeloma Clinical Study in the American Journal of HematologyToronto, Ontario--(Newsfile Corp. - May 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA), (the \"Company\" or \"Telo\"), a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications in oncology, is thrilled to announce that the manuscript titled, \"Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma\" was accepted for publication in the American Journal of Hematology. The article describes the significant results achieved with Telo's prognostic test for smoldering multiple myeloma (TeloViewSMM). The article is now available online on the Journal website at http://doi.org/10.1002/ajh.27364. The published study included a total of 168 smoldering multiple myeloma patients. The results described in the publication demonstrated superior performance characteristics compared to other oncology prognostic tests or scoring systems in smoldering multiple myeloma (\"SMM\"), particularly for SMM but also across other cancers as well. In the published independent validation included in the study, the TeloView test scored an 85% positive predictive value (accuracy in identifying high risk patients) and a 73% negative predictive value (accuracy in identifying stable patients), with associated sensitivity & specificity of 83% & 76%, respectively.The study was conducted in collaboration with Mayo Clinic, with Dr. Shaji Kumar, Professor of Medicine at Mayo Clinic and Chair of the National Comprehensive Cancer Network (NCCN) Myeloma Committee, as the Principle Clinical Investigator. The publication was co-authored by Dr. Kenneth Anderson, Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. The publication was also co-authored by Dr. Vincent Raj Kumar, Professor of Medicine, Dr. Dragan Jevremovic, Professor of Medicine and Pathology, and Dr. Robert Kyle, Professor of Medicine and Laboratory Medicine and Pathology, all from Mayo Clinic, and by Dr. Sabine Mai, Professor at the University of Manitoba, and co-Founder of Telo Genomics.Dr. Shaji Kumar, the Study Principle Clinical In...